CMS Entry id: 2709 | Channel: Blog landing page | Template: blog/index

Login
Facebook YouTube Twitter Linkedin
Facebook YouTube Twitter Linkedin

Blog

12 April 2018

A solution for improving recruitment into early Alzheimer’s disease clinical trials

Screening patients into early stage Alzheimer’s trials can be costly and time-consuming. Kenton Zavitz, PhD, Director of Clinical Affairs proposes a potential solution for improving recruitment into clinical trials. 


9 April 2018

The challenge of detecting early Alzheimer’s disease for clinical trials

In this post, Director of Clinical Affairs, Dr Kenton Zavitz, looks at the challenge of recruiting the correct patients into Alzheimer's disease trials.

7 April 2018

Exploring participant-level trajectories of cognitive performance in patients with schizophrenia

Cambridge Cognition and Boehringer Ingelheim have been investigating cognitive performance among patients with schizophrenia, with a view to improving future pro-cognitive drug trial designs. Our Director of Neuroscience, Dr Kiri Granger, presented the latest findings at ISCTM and SIRS.

6 April 2018

Affective face processing in schizophrenia: disorder-specific or transdiagnostic deficit?

Our recent review of meta-analyses concluded that facial emotion recognition deficits are common across a range of psychiatric, neurological and developmental disorders.

Our Senior Scientist, Dr Jack Cotter, presented the latest findings at Schizophrenia International Research Society (SIRS) conference.

5 April 2018

Comparing visuospatial associative learning for a middle-aged birth cohort and patients with schizophrenia

Visuospatial memory is extremely heterogeneous in schizophrenia. In a large population study, around a fifth of patients with schizophrenia showed similar errors rates to the top 50% of the general population. Conversely, half of the patients sampled showed substantial impairments. 

26 March 2018

How to choose the right assessment of spatial planning for your study

The Stockings of Cambridge (SOC) and One-Touch Stockings of Cambridge (OTS) tasks both assess the processes involved in spatial planning, but which is more appropriate for different participant groups? It all depends on the absence or presence of cognitive or motor impairments. 

7 March 2018

What does the new FDA guidance mean for clinical trials in early Alzheimer’s disease?

The latest FDA draft guidance for clinical trials in early Alzheimer’s disease presents many new opportunities and challenges for drug development. 

web-based testing, wearables, voice-based assessment, voice recognition, virtual clinical trials, trial design, transdiagnostic, test-retest, technology, spatial planning, social cognition, set-shifting, screening, schizotypal disorder, schizophrenia research, schizophrenia, rule learning, risk-taking, reversal, research funding, remote testing, reliability, regulations, recruitment, prodromal, pro-cognitive, pre-screening, pre-clinical, pen-and-paper, patient-centric, patient screening, patient reported outcomes, patient recruitment, patient finding, parkinson's disease, pal, outcome measures, ots, online, objective measures, novel, neurotech, neuroscience, multiple sclerosis, ms, methodology, mental health, mci, major depression, machine learning, innovate uk, impulsive, ied, guidance, gambling, fda, episodic memory, emotion recognition, ebbinghaus, early alzheimer's disease, drug development, dopamine, digital tools, digital health, depression, dementias platform uk, dementia, deep and frequent phenotyping, cognitive wellbeing, cognitive testing, cognitive science, cognitive safety, cognitive impairment, cognitive function, cognitive dysfunction, cognitive deficits, cognitive biomarkers, cognitive assessment, cognition kit, cognition, cns summit, clinical trials, clinical trial, clinical symptoms, cias, cardiovascular disease, cardiology, cantab research grant, cantab for clinical trials, cantab, cambridge gambling task, brain health, biomarkers, awards, automatic speech recognition, automated, attention, alzheimer's disease, affective cognition, aaic,